Pronk, L C <br/><br/>
Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.  [electronic resource] 

 -  Anti-cancer drugs  Oct 1998 
 - 759-64 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0959-4973 
<br/><br/><label>Standard No.: </label>10.1097/00001813-199810000-00003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents, Phytogenic--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Dexamethasone--therapeutic use<br/>Docetaxel<br/>Female<br/>Glucocorticoids--therapeutic use<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Nervous System Diseases--chemically induced<br/>Paclitaxel--adverse effects<br/>Prospective Studies<br/>Taxoids